Free shipping on all orders over $ 500

Mubritinib

Cat. No. M1919

All AbMole products are for research use only, cannot be used for human consumption.

Mubritinib Structure
Synonym:

TAK-165

Size Price Availability
10mg USD 60  USD60 Out of stock
50mg USD 200  USD200 Out of stock
100mg USD 350  USD350 Out of stock
200mg USD 620  USD620 Out of stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Mubritinib (TAK-165) is a novel HER2 selective tyrosine kinase inhibitor for the treatment of cancer. Mubritinib displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. Mubritinib displays no inhibitory activities against PC-3 cells with HER2 expressed very faintly with IC50 of 4.62 μM, as well as EGFR-overexpressing HT1376 and ACHN cell lines with IC50 of >25 μM. Mubritinib exhibits potent antiproliferative effects in ErbB2-overexpressing cancer cell lines (IC50 = 5 nM in BT474 breast cancer cells) and significantly inhibits bladder, breast and prostate cancer xenograft growth in vivo. Mubritinib (TAK-165) significantly inhibited growth of UMUC-3, ACHN, and LN-REC4 in the xenograft model. The antitumor effect (T/C [%]=growth of Mubritinib (TAK-165) treated tumor/average growth of control tumorx100) after 14 days treatment were 22.9%, 26.0%, and 26.5% in UMUC3, ACHN and LN-REC4, respectively.

Chemical Information
Molecular Weight 468.47
Formula C25H23F3N4O2
CAS Number 366017-09-6
Solubility (25°C) DMSO 25 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Nagasawa J, et al. Int J Urol. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.

Related EGFR/HER2 Products
Sevabertinib

Sevabertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with antitumor activity.

BPIQ-I

BPIQ-I (PD 159121) is a potent and ATP-competitive EGFR tyrosine kinase inhibitor..

HKI-357 

HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 with IC50s of 34 nM and 33 nM, respectively.

SJF-1528 

SJF-1528 is a potent EGFR PROTAC degrader with DC50 values of 39.2 nM and 736.2 nM for wild-type EGFR in OVCAR8 cells and Exon 20 Ins mutated EGFR in HeLa cells.

CH7233163 

CH7233163 is a noncovalent ATP-competitive inhibitor for EGFR-Del19/T790M/C797S.

  Catalog
Abmole Inhibitor Catalog




Keywords: Mubritinib, TAK-165 supplier, EGFR/HER2, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.